Can Brisk Walking Combined With Ingestion of a Lipid-lowering Drug Improve Fat Metabolism in Muscle?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Briefly, participants will be assessed for their eligibility for the study using an oral glucose tolerance test, which involves drinking a sugary drink followed by a series of small blood samples. If eligible, participants will be asked to take part in a fitness test and then two trials which will involve walking on a treadmill at a steady pace. Before and after the exercise a small piece of muscle will be taken from their thigh under local anaesthesia, as well as several small blood samples. Muscle muscle samples will be assessed for lipid metabolites.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Can the Health Benefits of a Walking-based Exercise Programme be Enhanced by Co-ingestion of a Lipid-lowering Drug?

NCT03809793

Pre-diabetes

COMPLETED NA

Walking Before or After Breakfast - Which is Better to Improve Health in Overweight Individuals?

NCT06240663

Metabolic Disease Insulin Resistance

COMPLETED NA

Effect of Exercise on Insulin Resistance

NCT01941277

Prediabetic State

TERMINATED NA

Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity

NCT02043405

Diabetes Pre-diabetes

COMPLETED NA

Effect of Exercise on Metabolic Health

NCT02001142

Obesity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The accumulation of fat in skeletal muscle is linked with insulin resistance in obesity and T2D. However, fat also accumulates in the muscle of lean, healthy people, but they remain insulin sensitive. This is because healthy people are able to burn this fat to generate energy during exercise. However, overweight/obese inactive people can't use muscle fat during exercise in the same manner, which is related to the high blood lipid concentrations that are observed in these individuals. Acipimox is a lipid-lowering agent that specifically reduces the breakdown of fat in adipose tissue and has been shown improve the blood lipid profile of obese individuals and T2D patients, at least in the short-term (1-2 weeks). Previous research has shown that the combination of Acipimox with exercise restores the ability of obese people to burn fat during moderate-intensity cycling exercise. It is now important to test whether Acipimox also increases the ability to burn muscle fat during low-intensity walking in people with prediabetes. If it does, then the next step will be to test whether the combination of Acipimox and walking can lead to improved insulin sensitivity and reduced T2D risk over a longer intervention programme. Twelve people with pre-diabetes will be recruited to undertake two experimental trials in a randomised order. Each trial will involve walking for 45 minutes on a treadmill, with muscle biopsies obtained from the thigh before (basal), immediately following (post-exercise) and 3 h post-exercise. Each trial will be identical, except that participants will ingest either Acipimox or a placebo in a double-blind design. Muscle biopsies will be used to examine differences in muscle fat between the two trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This study involves 2 trials. Each trial will involve walking for 45 minutes on a treadmill, with muscle biopsies obtained from the thigh before (basal), immediately following (post-exercise) and 3 h post-exercise. Each trial will be identical, except that participants will ingest either Acipimox or a placebo in a double-blind design. Muscle biopsies will be used to examine differences in muscle fat between the two trials

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acipimox ingestion

Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test. Following this, participants will ingest 250 mg of Acipimox, before undertaking 45 minutes walking on a treadmill. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.

Group Type EXPERIMENTAL

Body Composition

Intervention Type DIAGNOSTIC_TEST

Participants undergo a 5 minute body scan to determine their body composition.

Maximal aerobic fitness test

Intervention Type DIAGNOSTIC_TEST

Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.

Oral glucose tolerance test

Intervention Type DIAGNOSTIC_TEST

Participants will undergo an OGTT to determine insulin sensitivity.

Muscle biopsy

Intervention Type OTHER

Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.

Blood samples

Intervention Type OTHER

Participants will give 16 blood samples, to be assessed for fatty acids in the blood.

No drug

Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test.Participants will then undergo a 45 minute walk on a treadmill with no Acipimox ingestion. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.

Group Type OTHER

Body Composition

Intervention Type DIAGNOSTIC_TEST

Participants undergo a 5 minute body scan to determine their body composition.

Maximal aerobic fitness test

Intervention Type DIAGNOSTIC_TEST

Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.

Oral glucose tolerance test

Intervention Type DIAGNOSTIC_TEST

Participants will undergo an OGTT to determine insulin sensitivity.

Muscle biopsy

Intervention Type OTHER

Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.

Blood samples

Intervention Type OTHER

Participants will give 16 blood samples, to be assessed for fatty acids in the blood.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Body Composition

Participants undergo a 5 minute body scan to determine their body composition.

Intervention Type DIAGNOSTIC_TEST

Maximal aerobic fitness test

Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.

Intervention Type DIAGNOSTIC_TEST

Oral glucose tolerance test

Participants will undergo an OGTT to determine insulin sensitivity.

Intervention Type DIAGNOSTIC_TEST

Muscle biopsy

Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.

Intervention Type OTHER

Blood samples

Participants will give 16 blood samples, to be assessed for fatty acids in the blood.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 25-55 years
* Overweight or obese (BMI \>28 kg.m-2)
* Have prediabetes
* Not currently using any anti-diabetes medication
* Physically inactive (performing less than two 30 min structured exercise sessions per week for the last year)
* Not pregnant (or intending to get pregnant during the study) or currently breast feeding
* Pre-menopausal
* Not currently involved in a weight loss programme or using weight loss medication

Exclusion Criteria

* Involved in regular exercise (engaged in more than 2 sessions of structured exercise of \>30 min per week)
* Currently using anti-diabetes medication (e.g. insulin, metformin)
* Currently using niacin/vitamin B3 supplements
* Pregnant or breast feeding
* Currently engaged in active weight loss programmes or using weight loss medication
* Diagnosed with chronic kidney disease

Minimum Eligible Age

25 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No